MR imaging of soft-tissue masses

role of gadopentetate dimeglumine.

R. A. Benedikt, J. S. Jelinek, M. J. Kransdorf, R. P. Moser, B. H. Berrey

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To assess the effectiveness of gadopentetate dimeglumine in the magnetic resonance (MR) imaging evaluation of soft-tissue masses without osseous involvement, 30 patients underwent MR imaging before and after administration of contrast material (0.1 mmol/kg). Of the 30 lesions, 22 were benign and eight were malignant; histologic confirmation was available in all lesions except one benign lesion. Overall, enhancement was detected in 26 (87%) of 30 lesions: 18 (82%) of the 22 benign lesions and eight (100%) of eight malignant lesions. Enhancement was characterized as homogeneous (two [11%] benign lesions, two [25%] malignant lesions), inhomogeneous (11 [61%] benign lesions, six [75%] malignant lesions), or peripheral (five [28%] benign lesions, no malignant lesions). Of the 19 lesions assessed for a change in enhancement over time, seven (37%) showed an increase and two (11%) showed a decrease in signal intensity. The authors conclude that benign and malignant soft-tissue lesions could not be differentiated solely on the basis of enhancement (pattern, degree, or time course).

Original languageEnglish (US)
Pages (from-to)485-490
Number of pages6
JournalJournal of magnetic resonance imaging : JMRI
Volume4
Issue number3
StatePublished - May 1994
Externally publishedYes

Fingerprint

Gadolinium DTPA
Magnetic Resonance Imaging
Contrast Media

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Benedikt, R. A., Jelinek, J. S., Kransdorf, M. J., Moser, R. P., & Berrey, B. H. (1994). MR imaging of soft-tissue masses: role of gadopentetate dimeglumine. Journal of magnetic resonance imaging : JMRI, 4(3), 485-490.

MR imaging of soft-tissue masses : role of gadopentetate dimeglumine. / Benedikt, R. A.; Jelinek, J. S.; Kransdorf, M. J.; Moser, R. P.; Berrey, B. H.

In: Journal of magnetic resonance imaging : JMRI, Vol. 4, No. 3, 05.1994, p. 485-490.

Research output: Contribution to journalArticle

Benedikt, RA, Jelinek, JS, Kransdorf, MJ, Moser, RP & Berrey, BH 1994, 'MR imaging of soft-tissue masses: role of gadopentetate dimeglumine.', Journal of magnetic resonance imaging : JMRI, vol. 4, no. 3, pp. 485-490.
Benedikt RA, Jelinek JS, Kransdorf MJ, Moser RP, Berrey BH. MR imaging of soft-tissue masses: role of gadopentetate dimeglumine. Journal of magnetic resonance imaging : JMRI. 1994 May;4(3):485-490.
Benedikt, R. A. ; Jelinek, J. S. ; Kransdorf, M. J. ; Moser, R. P. ; Berrey, B. H. / MR imaging of soft-tissue masses : role of gadopentetate dimeglumine. In: Journal of magnetic resonance imaging : JMRI. 1994 ; Vol. 4, No. 3. pp. 485-490.
@article{47bfc1c5280440b388cd44eac495a5e2,
title = "MR imaging of soft-tissue masses: role of gadopentetate dimeglumine.",
abstract = "To assess the effectiveness of gadopentetate dimeglumine in the magnetic resonance (MR) imaging evaluation of soft-tissue masses without osseous involvement, 30 patients underwent MR imaging before and after administration of contrast material (0.1 mmol/kg). Of the 30 lesions, 22 were benign and eight were malignant; histologic confirmation was available in all lesions except one benign lesion. Overall, enhancement was detected in 26 (87{\%}) of 30 lesions: 18 (82{\%}) of the 22 benign lesions and eight (100{\%}) of eight malignant lesions. Enhancement was characterized as homogeneous (two [11{\%}] benign lesions, two [25{\%}] malignant lesions), inhomogeneous (11 [61{\%}] benign lesions, six [75{\%}] malignant lesions), or peripheral (five [28{\%}] benign lesions, no malignant lesions). Of the 19 lesions assessed for a change in enhancement over time, seven (37{\%}) showed an increase and two (11{\%}) showed a decrease in signal intensity. The authors conclude that benign and malignant soft-tissue lesions could not be differentiated solely on the basis of enhancement (pattern, degree, or time course).",
author = "Benedikt, {R. A.} and Jelinek, {J. S.} and Kransdorf, {M. J.} and Moser, {R. P.} and Berrey, {B. H.}",
year = "1994",
month = "5",
language = "English (US)",
volume = "4",
pages = "485--490",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - MR imaging of soft-tissue masses

T2 - role of gadopentetate dimeglumine.

AU - Benedikt, R. A.

AU - Jelinek, J. S.

AU - Kransdorf, M. J.

AU - Moser, R. P.

AU - Berrey, B. H.

PY - 1994/5

Y1 - 1994/5

N2 - To assess the effectiveness of gadopentetate dimeglumine in the magnetic resonance (MR) imaging evaluation of soft-tissue masses without osseous involvement, 30 patients underwent MR imaging before and after administration of contrast material (0.1 mmol/kg). Of the 30 lesions, 22 were benign and eight were malignant; histologic confirmation was available in all lesions except one benign lesion. Overall, enhancement was detected in 26 (87%) of 30 lesions: 18 (82%) of the 22 benign lesions and eight (100%) of eight malignant lesions. Enhancement was characterized as homogeneous (two [11%] benign lesions, two [25%] malignant lesions), inhomogeneous (11 [61%] benign lesions, six [75%] malignant lesions), or peripheral (five [28%] benign lesions, no malignant lesions). Of the 19 lesions assessed for a change in enhancement over time, seven (37%) showed an increase and two (11%) showed a decrease in signal intensity. The authors conclude that benign and malignant soft-tissue lesions could not be differentiated solely on the basis of enhancement (pattern, degree, or time course).

AB - To assess the effectiveness of gadopentetate dimeglumine in the magnetic resonance (MR) imaging evaluation of soft-tissue masses without osseous involvement, 30 patients underwent MR imaging before and after administration of contrast material (0.1 mmol/kg). Of the 30 lesions, 22 were benign and eight were malignant; histologic confirmation was available in all lesions except one benign lesion. Overall, enhancement was detected in 26 (87%) of 30 lesions: 18 (82%) of the 22 benign lesions and eight (100%) of eight malignant lesions. Enhancement was characterized as homogeneous (two [11%] benign lesions, two [25%] malignant lesions), inhomogeneous (11 [61%] benign lesions, six [75%] malignant lesions), or peripheral (five [28%] benign lesions, no malignant lesions). Of the 19 lesions assessed for a change in enhancement over time, seven (37%) showed an increase and two (11%) showed a decrease in signal intensity. The authors conclude that benign and malignant soft-tissue lesions could not be differentiated solely on the basis of enhancement (pattern, degree, or time course).

UR - http://www.scopus.com/inward/record.url?scp=0028432773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028432773&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 485

EP - 490

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 3

ER -